This agent may be an alternative for patients with pain severe enough to require around-the-clock, long-term opioid therapy when other options are inadequate.
Through screening for early detection of cognitive impairment and dementia, patients have a better chance of managing their diabetes at home with provider assistance.
The proposed rule will replace existing regulations and provide detailed, current information for patients and their providers.
This article reviews five new drugs (umeclidinium and vilanterol, vortioxetine, dapagliflozin, luliconazole, sofosbuvir) that were approved by the FDA in the past year.
Five new molecular entities (riociguat, ibrutinib, obinutuzumab, coagulation factor XIII A-subunit [recombinant], collagenase clostridium histolyticum) that were recently approved by the FDA are discussed.